Inactive Instrument

Merck & Co., Inc. Share Price Euronext Paris

Equities

MRK

US58933Y1055

Pharmaceuticals

Financials

Sales 2024 * 64.18B 59.87B 5,359B Sales 2025 * 68.68B 64.08B 5,735B Capitalization 328B 306B 27,384B
Net income 2024 * 19.51B 18.2B 1,629B Net income 2025 * 22.25B 20.76B 1,858B EV / Sales 2024 * 5.4 x
Net Debt 2024 * 18.6B 17.36B 1,553B Net Debt 2025 * 7.28B 6.79B 608B EV / Sales 2025 * 4.88 x
P/E ratio 2024 *
16.7 x
P/E ratio 2025 *
14.5 x
Employees 71,000
Yield 2024 *
2.39%
Yield 2025 *
2.53%
Free-Float 70.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 01/14/01
Director of Finance/CFO 55 01/90/01
Chief Tech/Sci/R&D Officer 55 01/20/01
Members of the board TitleAgeSince
Director/Board Member 63 27/07/27
Director/Board Member 67 01/15/01
Director/Board Member 69 01/18/01
More insiders
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company